JPH0411525B2 - - Google Patents

Info

Publication number: JPH0411525B2
Authority: JP; Japan
Prior art keywords: protoporphyrin; bilirubin; heme; tin; chromium
Prior art date: 1982-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP57502582A

Other languages

English (en)

Japanese (ja)

Other versions

JPS58501130A (ja

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-07-15

Filing date

1982-07-15

Publication date

1992-02-28

1982-07-15 Application filed filed Critical

1982-07-15 Priority claimed from PCT/US1982/000955 external-priority patent/WO1983000287A1/en

1983-07-14 Publication of JPS58501130A publication Critical patent/JPS58501130A/ja

1992-02-28 Publication of JPH0411525B2 publication Critical patent/JPH0411525B2/ja

Status Granted legal-status Critical Current

Links

BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 66
229950003776 protoporphyrin Drugs 0.000 description 44
239000000203 mixture Substances 0.000 description 25
150000003278 haem Chemical class 0.000 description 20
238000000034 method Methods 0.000 description 20
102000016761 Haem oxygenases Human genes 0.000 description 16
108050006318 Haem oxygenases Proteins 0.000 description 16
230000000694 effects Effects 0.000 description 14
241000124008 Mammalia Species 0.000 description 13
241001465754 Metazoa Species 0.000 description 10
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
239000007864 aqueous solution Substances 0.000 description 8
230000037396 body weight Effects 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
230000004060 metabolic process Effects 0.000 description 6
230000037323 metabolic rate Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
238000011282 treatment Methods 0.000 description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
229910052718 tin Inorganic materials 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010023138 Jaundice neonatal Diseases 0.000 description 2
201000006346 Neonatal Jaundice Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
208000007056 sickle cell anemia Diseases 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
208000021130 Bilirubin encephalopathy Diseases 0.000 description 1
GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
208000022806 beta-thalassemia major Diseases 0.000 description 1
QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
208000035623 congenital anemia Diseases 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
208000006663 kernicterus Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000001126 phototherapy Methods 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
230000002028 premature Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
235000011121 sodium hydroxide Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000011421 subcutaneous treatment Methods 0.000 description 1
239000011135 tin Substances 0.000 description 1
150000003606 tin compounds Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000006276 transfer reaction Methods 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Landscapes

Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP57502582A 1981-07-15 1982-07-15 ヘムの代謝速度の低下方法 Granted JPS58501130A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US285373FREGB		1981-07-15
PCT/US1982/000955 WO1983000287A1 (en)	1981-07-15	1982-07-15	Method of decreasing the rate of heme metabolism and composition used therefor

Publications (2)

Publication Number	Publication Date
JPS58501130A JPS58501130A (ja)	1983-07-14
JPH0411525B2 true JPH0411525B2 (de)	1992-02-28

Family

ID=22168093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57502582A Granted JPS58501130A (ja)	1981-07-15	1982-07-15	ヘムの代謝速度の低下方法

Country Status (1)

Country	Link
JP (1)	JPS58501130A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7375216B2 (en)	2002-06-04	2008-05-20	Infacare Pharmaceutical Corporation	Preparation of metal mesoporphyrin compounds
JP5524622B2 (ja)	2006-10-04	2014-06-18	インファケアファーマスーティカル，コーポレイション	スタンソポルフィンの高純度で大規模な製造
ES2609110T3 (es)	2011-03-30	2017-04-18	Infacare Pharmaceutical Corporation	Procedimientos de síntesis de mesoporfirinas metálicas

1982
- 1982-07-15 JP JP57502582A patent/JPS58501130A/ja active Granted

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA=1981 *

Also Published As

Publication number	Publication date
JPS58501130A (ja)	1983-07-14

Publication	Publication Date	Title
DE602004008927T2 (de)	2008-06-05	Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
Dennery	2002	Pharmacological interventions for the treatment of neonatal jaundice
CA1293504C (en)	1991-12-24	Therapeutic use of tin mesoporphyrin
EP1115389B1 (de)	2014-03-12	Antagonisten und agonisten der fructosamin oxidase
US5010073A (en)	1991-04-23	Use of liposomes as carriers for metalloporphyrins
US4668670A (en)	1987-05-26	Tin diiododeuteroporphyrin and therapeutic use thereof
Bishop et al.	1998	Pyrroloquinoline quinone: a novel vitamin?
Drummond et al.	1984	An experimental model of postnatal jaundice in the suckling rat. Suppression of induced hyperbilirubinemia by Sn-protoporphyrin.
EP0188277A2 (de)	1986-07-23	Metall-Protoporphyrins zur Kontrolle des Tryptophanmetabolismus
US4692440A (en)	1987-09-08	Therapeutic use of tin mesoporphyrin
US4684637A (en)	1987-08-04	Method of decreasing rate of heme metabolism
US4699903A (en)	1987-10-13	Therapeutic use of tin diiododeuteroporphyrin
Drummond et al.	1982	Suppression of hyperbilirubinemia in the rat neonate by chromium-protoporphyrin. Interactions of metalloporphyrins with microsomal heme oxygenase of human spleen.
EP0084053B1 (de)	1987-09-09	Arzneimittel und die Verwendung von Sn- oder Cr-Protoporphyrin zu dessen Herstellung
Vreman et al.	2001	Alternative metalloporphyrins for the treatment of neonatal jaundice
US5223494A (en)	1993-06-29	Orally administered porphyrins to control intestinal iron absorption
JP3251673B2 (ja)	2002-01-28	酸化窒素生成の抑制方法
AU595047B2 (en)	1990-03-22	Therapeutic use of tin diiododeuteroporphyrin
EP0199888A2 (de)	1986-11-05	Kontrolle der Häm- und Eisenkonzentrationen im Körpergewebe
US6380254B2 (en)	2002-04-30	Method and composition for treating and preventing pathogenic effects caused by intracellular calcium overload
JPS58501130A (ja)	1983-07-14	ヘムの代謝速度の低下方法
US10875834B2 (en)	2020-12-29	Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives
Lindeman et al.	2025	Runaway uncoupling in 2, 4-dinitrophenol poisoning: Clinical and mitochondrial observations from two cases
JP3035343B2 (ja)	2000-04-24	腸内鉄吸収性を制御するための経口投与ポルフィリン類
RU2776671C2 (ru)	2022-07-22	Применение клатратного комплекса 20-гидроксиэкдизона с арабиногалактаном для нормализации обмена веществ, повышения неспецифической резистентности, роста и развития животных